Genentech developed Venclexta in combination with Azacitidine for the treatment of patients with Myelodysplastic Syndromes.
Venclexta® in combination with Azacitidine has the ability to treat adult patients who have formerly untreated with intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the revised International Prognostic Scoring System (IPSS-R).
Venclexta, first-in-class targeted therapy produced to bind and inhibit the B-cell lymphoma-2 (BCL-2) protein.In some blood cancers and tumors it is noticed that BCL-2 builds up and restricts cancer cells from dying or self-destructing, which is known as apoptosis.
Some of the side effects of Venclextain combination with Azacitidine results in lowering white blood cell count, diarrhea, shortness of breath, tiredness, cough, muscle and joint pain, vomiting, dizziness, sore throat and low blood pressure.
Myelodysplastic Syndromes (MDS) are group of blood cancers causing weakness, anemia, frequent infections, and debilitating fatigue affecting the person’s quality of life. It affects the ability of the bone marrow to produce normal blood cells. In few cases, MDS may also lead to acute myeloid leukemia (AML).
U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD)Venclexta® (venetoclax) in combination with azacitidine for the treatment of Myelodysplastic Syndromes.
